Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy
British Journal of Clinical Pharmacology · 2025-04 · 91 (4) · 989-1002
DOI: 10.1111/bcp.16006 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 10.02.2024. Verfasst von Shakir Atoyebi und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Rilpivirine, Pyridones, Models, Biological, HIV Infections. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Aims
Long‐acting cabotegravir and rilpivirine have been approved to manage HIV in adults, but data regarding safe use in pregnancy are limited. Physiologically‐based pharmacokinetic (PBPK) modelling was used to simulate the approved dosing regimens in pregnancy and explore if C trough was maintained above cabotegravir and rilpivirine target concentrations (664 and 50 ng/mL, respectively).
Methods
An adult PBPK model was validated using clinical data of cabotegravir and rilpivirine in nonpregnant adults. This was modified by incorporating pregnancy‐induced metabolic and physiological changes. The pregnancy PBPK model was validated with data on oral rilpivirine and raltegravir (UGT1A1 probe substrate) in pregnancy. Twelve weeks' disposition of monthly and bimonthly dosing of long‐acting cabotegravir and rilpivirine was simulated at different trimesters and foetal exposure was also estimated.
Results
Predicted C trough at week 12 for monthly long‐acting cabotegravir was above 664 ng/mL throughout pregnancy, but below the target in 0.5% of the pregnant population in the third trimester with bimonthly long‐acting cabotegravir. Predicted C trough at week 12 for monthly and bimonthly long‐acting rilpivirine was below 50 ng/mL in at least 40% and over 90% of the pregnant population, respectively, throughout pregnancy. Predicted medians (range) of cord‐to‐maternal blood ratios were 1.71 (range, 1.55‐1.79) for cabotegravir and 0.88 (0.78‐0.93) for rilpivirine between weeks 38 and 40.
Conclusions
Model predictions suggest that monthly long‐acting cabotegravir could maintain antiviral efficacy throughout pregnancy, but that bimonthly administration may require careful clinical evaluation. Both monthly and bimonthly long‐acting rilpivirine may not adequately maintain antiviral efficacy in pregnancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Liverpool, Liverpool, UK.
ORCID-Profile: Shakir Atoyebi, Maiara Camotti Montanha, Adeniyi Olagunju, Catriona Waitt
Förderung
- Wellcome Trust
Zitieren
APA
Atoyebi, S., Bunglawala, F., Cottura, N., Grañana-Castillo, S., Montanha, M. C., Olagunju, A., Siccardi, M., & Waitt, C. (2025). Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy. British Journal of Clinical Pharmacology, 91(4), 989-1002. https://doi.org/10.1111/bcp.16006
Vancouver
Atoyebi S, Bunglawala F, Cottura N, Grañana-Castillo S, Montanha MC, Olagunju A, et al. Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy. British Journal of Clinical Pharmacology. 2025;91(4):989-1002. doi:10.1111/bcp.16006
BibTeX
@article{Atoyebi2025,
author = {Atoyebi, Shakir and Bunglawala, Fazila and Cottura, Nicolas and Grañana-Castillo, Sandra and Montanha, Maiara Camotti and Olagunju, Adeniyi and Siccardi, Marco and Waitt, Catriona},
title = {Physiologically‐based pharmacokinetic modelling of long‐acting injectable cabotegravir and rilpivirine in pregnancy},
journal = {British Journal of Clinical Pharmacology},
year = {2025},
volume = {91},
number = {4},
pages = {989--1002},
doi = {10.1111/bcp.16006}
}
EUVIMED